Replies to post #13940 on Mast Therapeutics, Inc. (MSTX)

[alexander77]

I am back in. Reason: I am 100 % sure that Mast Therapeutics is able to improve the previous phase 3 trial for sickle cell from p=0.07 to p=.05 or lower. The company did significant adjustments (Hydroxurea, average age below 16 years, the biggest trial ever on sickle cell, ...) to succesfully complete this goal. Above that the FDA will be VERY happy that the opioid use and possible opioid addiction/abuse can be reduced by Vepoloxamer for sickle cell patients. It is a public secret that the FDA wants to get rid of opioids.